BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS) has been accepted for inclusion in the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham. The study, supported by a grant from the ALS Association, wil ...

BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its senior leadership team will present at the prestigious Jefferies London Healthcare Conference. Chief Executive Officer Ivor Elrifi and Chief Operating Officer/Chief Financial Officer Keeren Sha ...

Tiziana Life Sciences Ltd. ( TLSA ) is a biotech company that develops Foralumab, an anti-CD3 monoclonal antibody. This was designed for intranasal delivery to modulate immune responses in the brain. Foralumab aims to induce regulatory T cells (Tregs) and calmMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degre ...

Group 1 - Tiziana Life Sciences Ltd. (TLSA) is a biotech company focused on developing Foralumab, an anti-CD3 monoclonal antibody designed for intranasal delivery to modulate immune responses in the brain [1] - Foralumab aims to induce regulatory T cells (Tregs) to help calm immune responses [1]

Core Viewpoint - Tiziana Life Sciences is advancing its second asset, TZLS-501, a fully human anti-IL-6 receptor monoclonal antibody, amidst increased industry activity in the IL-6 pathway, highlighted by Novartis' acquisition of Tourmaline Bio for approximately $1.4 billion [1][3]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies, particularly intranasal administration [9][10]. Product Development - TZLS-501 targets both membrane-bound and soluble forms of IL-6R, potentially offering therapeutic advantages in managing diseases characterized by excessive IL-6 signaling, such as rheumatoid arthritis, acute respiratory distress syndrome, and various cancers [2][4]. - The company plans to pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to advance its lead program, intranasal foralumab [1][3]. Market Context - The recent acquisition by Novartis underscores the growing importance of IL-6 therapeutics, positioning Tiziana to capitalize on this trend with the development of TZLS-501 [3][5]. - The dual mechanism of action of TZLS-501, which inhibits IL-6R signaling and reduces circulating IL-6 cytokines, is seen as a significant advancement in treating acute and chronic inflammatory conditions [2][6]. Clinical Programs - Foralumab, Tiziana's lead candidate, is currently being studied in clinical trials for its efficacy in treating non-active secondary progressive multiple sclerosis, with positive outcomes reported in initial patient dosing [7][8].

Group 1 - The article discusses Tiziana Life Sciences (NASDAQ: TLSA) and its ongoing drug development efforts, particularly focusing on the Foralumab drug and its additional Expanded Access Program (EAP) enrollment [2] - The author is affiliated with Biotech Analysis Central, which provides extensive analysis and resources for healthcare investors, including a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [2] - The service offered by Biotech Analysis Central is priced at $49 per month, with a yearly plan available at a discounted rate of $399, representing a 33.50% discount [1] Group 2 - The article does not provide specific financial data or performance metrics related to Tiziana Life Sciences or its products [4] - There are no disclosed positions or plans to initiate positions in the companies mentioned, indicating a neutral stance from the author [3]

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by intranasal foralumab represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases. NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing bre ...